Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Alliance Pharma Leads 3 UK Penny Stocks To Consider

In This Article:

The UK market has been experiencing fluctuations, with the FTSE 100 and FTSE 250 indices recently closing lower due to weak trade data from China, highlighting global economic interdependencies. In such a climate, investors often seek opportunities in smaller or less-established companies that can offer potential value despite broader market challenges. While the term "penny stocks" may seem outdated, these stocks still represent an intriguing investment area for those focusing on companies with robust financials and growth potential.

Top 10 Penny Stocks In The United Kingdom

Name

Share Price

Market Cap

Financial Health Rating

Tristel (AIM:TSTL)

£3.75

£182.42M

★★★★★★

ME Group International (LSE:MEGP)

£2.06

£780M

★★★★★★

Begbies Traynor Group (AIM:BEG)

£0.93

£148.85M

★★★★★★

Polar Capital Holdings (AIM:POLR)

£4.885

£491.62M

★★★★★★

Foresight Group Holdings (LSE:FSG)

£3.67

£432.46M

★★★★★★

Next 15 Group (AIM:NFG)

£3.70

£343.12M

★★★★☆☆

Secure Trust Bank (LSE:STB)

£4.33

£85.44M

★★★★☆☆

Ultimate Products (LSE:ULTP)

£1.025

£90.69M

★★★★★★

Helios Underwriting (AIM:HUW)

£2.08

£148.39M

★★★★★☆

Stelrad Group (LSE:SRAD)

£1.425

£180.84M

★★★★★☆

Click here to see the full list of 446 stocks from our UK Penny Stocks screener.

We'll examine a selection from our screener results.

Alliance Pharma

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Alliance Pharma plc acquires, markets, and distributes consumer healthcare products and prescription medicines across various regions including Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas with a market cap of £330.83 million.

Operations: The company generates revenue from two main segments: Consumer Healthcare, contributing £136.21 million, and Prescription Medicines, accounting for £46.93 million.

Market Cap: £330.83M

Alliance Pharma is undergoing a significant transition with an acquisition deal set to delist it from AIM, as a consortium led by DBAY Advisors plans to buy the remaining shares for approximately £250 million. Despite being unprofitable with a negative return on equity of -15.07%, the company has managed its debt well, covering it through operating cash flow and maintaining a satisfactory net debt to equity ratio of 37.3%. While short-term assets exceed liabilities, long-term liabilities remain uncovered. The management team is experienced, though the board lacks tenure stability. The stock trades below estimated fair value despite recent volatility and insider selling.